- Home
- GDTC vs BOLD Comparison
GDTC vs BOLD Comparison
Compare GDTC & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- BOLD
- Stock Information
- Founded
- GDTC 2018
- BOLD 2018
- Country
- GDTC Singapore
- BOLD United States
- Employees
- GDTC N/A
- BOLD N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- GDTC Health Care
- BOLD
- Exchange
- GDTC Nasdaq
- BOLD Nasdaq
- Market Cap
- GDTC 21.5M
- BOLD 24.4M
- IPO Year
- GDTC 2023
- BOLD 2024
- Fundamental
- Price
- GDTC $1.86
- BOLD $1.20
- Analyst Decision
- GDTC Buy
- BOLD Buy
- Analyst Count
- GDTC 1
- BOLD 3
- Target Price
- GDTC $5.00
- BOLD $4.00
- AVG Volume (30 Days)
- GDTC 18.1K
- BOLD 105.5K
- Earning Date
- GDTC 01-01-0001
- BOLD 08-11-2025
- Dividend Yield
- GDTC N/A
- BOLD N/A
- EPS Growth
- GDTC N/A
- BOLD N/A
- EPS
- GDTC N/A
- BOLD N/A
- Revenue
- GDTC $368,838.00
- BOLD N/A
- Revenue This Year
- GDTC $5.37
- BOLD N/A
- Revenue Next Year
- GDTC N/A
- BOLD N/A
- P/E Ratio
- GDTC N/A
- BOLD N/A
- Revenue Growth
- GDTC N/A
- BOLD N/A
- 52 Week Low
- GDTC $1.20
- BOLD $1.00
- 52 Week High
- GDTC $4.05
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- GDTC 35.89
- BOLD N/A
- Support Level
- GDTC $1.85
- BOLD N/A
- Resistance Level
- GDTC $1.95
- BOLD N/A
- Average True Range (ATR)
- GDTC 0.10
- BOLD 0.00
- MACD
- GDTC -0.02
- BOLD 0.00
- Stochastic Oscillator
- GDTC 23.53
- BOLD 0.00
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.